PharmaShots | Incisive News in 3 Shots

Subscribe Now

imfinzi

Insights+: EMA Marketing Authorization of New Drugs in October 2023

Insights+: EMA Marketing Authorization of New Drugs in October 2023

November 23, 2023

AstraZeneca and Hutchmed Initiate P-III SAMETA Trial of Imfinzi (durvalumab) + Orpathys (savolitinib) for Advanced Papillary Renal Cell Carcinoma

AstraZeneca and Hutchmed Initiate P-III SAMETA Trial of Imfinzi (durvalumab) + Orpathys (savolitinib) for Advanced Papillary Renal...

November 1, 2021

AstraZeneca's Imfinzi (durvalumab) Receives EC's Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

AstraZeneca's Imfinzi (durvalumab) Receives EC's Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

September 2, 2020

AstraZeneca's Imfinzi (durvalumab) Receives MHLW's Approval for Extensive-Stage Small Cell Lung Cancer

AstraZeneca's Imfinzi (durvalumab) Receives MHLW's Approval for Extensive-Stage Small Cell Lung Cancer

August 21, 2020

AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Priority Review for Less Frequent Fixed-Dose Use in NSCLC and Bladder Cancer

AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Priority Review for Less Frequent Fixed-Dose Use in NSCLC and Bladder Can...

August 18, 2020

AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Approval for Extensive-Stage Small Cell Lung Cancer

AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Approval for Extensive-Stage Small Cell Lung Cancer

March 30, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us